October 18, 2016 08:09 AM EDT

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

Arsalan Arif

Founder

The executive crew at The Medicines Company say that they remain on track with an early-stage PCSK9 that reliably knocked down levels of bad cholesterol …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

Arsalan Arif

Founder

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus

The Med­i­cines Com­pa­ny touts fresh ev­i­dence that their PC­SK9si can durably bat down LDL

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

The Medicines Company touts fresh evidence that their PCSK9si can durably bat down LDL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Novartis to cut 139 jobs in NJ as part of commercial refocus